CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Aurisco

Aurisco Pharmaceutical Co., Ltd, (SSE Stock code: 605116) serves global markets with over 28 years’ experience in the development and cGMP manufacture of Active Pharmaceutical Ingredients (APIs) for global markets and finished dosage forms (FDFs) for domestic market.

It is the first and only USFDA inspected manufacturer of generic oligonucleotide APIs in the world, with 5 successful oligonucleotide validations, including ASOs and GalNAc-conjugated siRNAs.

With 6 R&D centers, 4 cGMP manufacturing sites and sales offices in USA, Portugal, India and Brazil, the company focuses on complex products for the most demanding customers in the most regulated markets, aiming to be a trusted, globally recognized pharmaceutical company. Our sites have been inspected by all major health authorities and audited frequently by customers.

With a broad portfolio of complex generic APIs and 40 USDMFs, the company is broadening its offer from chiral small molecules to GLP-1 peptides and oligonucleotides.

With a dedicated R&D Center for oligonucleotides and cGMP manufacturing lines in 2 sites (Yangzhou and Cangshan), Aurisco also offers CDMO services to innovators in modern, IP safe and cGMP and ESG compliant environment for research, development and manufacturing of their innovative molecules. Presently, Aurisco is a well-recognized CDMO for oligonucleotides and their phosphoramidites.

Having over 100 patents filled worldwide and more than 300 scientists, the company pays special attention to IP, innovation and sustainability. Being Ecovadis Gold ranked, Aurisco has joined the SBTi, M2030 and the Sustainable Procurement Pledge. Aurisco was the first pharmaceutical company in China to pass a RX360 supply chain security inspection and has been audited by the Pharmaceutical Supply Chain Initiative (PSCI), a group of pharmaceutical and healthcare companies who share a vision of better social, health, safety and environmental outcomes in the communities where they buy.

For further information, please visit our website www.aurisco.com and follow us on LinkedIn or contact info@aurisco.com.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026